The University of Edinburgh, Deanery of Biomedical Sciences, Edinburgh Medical School, College of Medicine & Veterinary Medicine, 1 George Square, Edinburgh, EH8 9JZ, UK; Orcid ID: https://orcid.org/0000-0002-9903-7086.
The University of Edinburgh, Deanery of Biomedical Sciences, Edinburgh Medical School, College of Medicine & Veterinary Medicine, 1 George Square, Edinburgh, EH8 9JZ, UK; Zhejiang University - University of Edinburgh Institute, Zhejiang University School of Medicine Zhejiang University, International Campus, 718 East Haizhou Road, Haining, 314400, China; Orcid ID: https://orcid.org/0000-0002-9903-7086.
Trends Parasitol. 2018 Oct;34(10):818-827. doi: 10.1016/j.pt.2018.08.006. Epub 2018 Sep 1.
Human African trypanosomiasis (HAT) is responsible for around 3000 reported cases each year. Treatments for HAT are expensive and problematic to administer, and available drugs are old and less than ideal, some with high levels of toxicity that result in debilitating and, in some cases, fatal side effects. Treatment options are limited, with only one drug, eflornithine, introduced in the last 28 years. Here we examine the limitations of current chemotherapeutic approaches to manage HAT, the constraints to new drug development exploring drug failures and new drugs on the horizon, and consider the epidemiological, political, social, and economic factors influencing drug development.
人类非洲锥虫病（HAT）每年导致约 3000 例报告病例。HAT 的治疗费用昂贵且给药存在问题，现有的药物陈旧且不理想，有些药物毒性很高，导致衰弱，在某些情况下甚至致命的副作用。治疗选择有限，在过去的 28 年中仅引入了一种药物，依氟鸟氨酸。在这里，我们研究了当前化疗方法治疗 HAT 的局限性，探索药物失败和新出现的药物的新药开发的限制，以及考虑影响药物开发的流行病学、政治、社会和经济因素。
